...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Prescrire international >Cancer risk in diabetic patients treated with insulin glargine?
【24h】

Cancer risk in diabetic patients treated with insulin glargine?

机译：用甘精胰岛素治疗的糖尿病患者患癌症的风险？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

? Insulin glargine was the first long-acting human insulin analogue to be authorised in the European Union, in the early 2000s, for the treatment of diabetes mellitus. It has about a 6-fold increase in affinity for the insulin-like growth factor 1 (EGF-1) receptor compared with natural human insulin, which may stimulate tumour development. ? Four European epidemiological studies published in 2009 examined the risk of cancer in diabetic patients treated with insulin glargine. ? One of these studies, conducted in Germany, showed a statistically significant dose-dependent increase in the risk of cancer. Two other studies, one in Scotland and the other in Sweden, showed an increase in the risk of breast cancer. The fourth study, conducted in the UK, showed a lower risk of cancer in patients on metformin. ? This evidence is inconclusive, notably because these studies did not take confounding factors into account. Nevertheless, the results tend to be similar and consistent with certain pharmacological mechanisms. ? In practice, pending more solid evidence, these epidemiological results should be taken into account when weighing the risk-benefit balance of insulin therapy for diabetic patients, on a case by case basis, depending on the type of diabetes, patient history, life expectancy, and the possible practical advantages of insulin glargine.
机译：？甘精胰岛素是第一个在2000年代初获得欧盟批准用于治疗糖尿病的长效人胰岛素类似物。与天然人胰岛素相比，它对胰岛素样生长因子1（EGF-1）受体的亲和力增加了约6倍，这可能会刺激肿瘤的发展。 ？ 2009年发表的四项欧洲流行病学研究调查了接受甘精胰岛素治疗的糖尿病患者患癌症的风险。 ？其中一项在德国进行的研究表明，统计学上显着的剂量依赖性增加癌症风险。另外两项研究，一项在苏格兰，另一项在瑞典，显示乳腺癌风险增加。在英国进行的第四项研究表明，服用二甲双胍的患者患癌症的风险较低。 ？该证据尚无定论，尤其是因为这些研究未考虑混杂因素。然而，结果趋于相似并且与某些药理机制一致。 ？实际上，在获得更确凿的证据之前，应根据糖尿病的类型，患者的病史，预期寿命，在不同情况下权衡糖尿病患者胰岛素治疗的风险收益平衡时，应考虑这些流行病学结果。以及甘精胰岛素的实际应用优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号